Abstract: A method for endo-phenotyping and risk stratifying obstructive sleep apnea (OSA) incudes acquiring signals associated with breathing over a period of time from a subject. In some embodiments, the signals associated with breathing are oxygen saturation signals (SpO2) that can be acquired using a SpO2 sensor. In some embodiments, the signals associated with breathing are snoring signals that can be acquired using an acoustic sensor. The method further includes determining at least one endo-phenotype of OSA using the acquired signals associated with breathing. In some embodiments, SpO2 signals can be used to determine endo-phenotypes including pharyngeal collapsibility, arousal threshold, ventilatory instability, hypoxic burden, and heart rate burden. In some embodiments, snoring signals can be used to determine endo-phenotypes including a site of airway collapse.

Abstract: In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the administration of these pharmaceutical compositions.